Nestle India Shares Tumble Nearly 3% as FSSAI Files Adjudication Cases Over Three Infant Nutrition Products

Shares of packaged consumer goods heavyweight Nestle India Ltd came under severe selling pressure on Friday, September 18, falling nearly 3% intraday after India's apex food regulator initiated formal legal action against the company over alleged violations across three infant nutrition products.

The Food Safety and Standards Authority of India (FSSAI) has filed three separate adjudication cases against Nestle India following regulatory scrutiny of products and promotional material displayed on e-commerce platforms, as well as laboratory testing results.

Regulatory Scrutiny on Promotional Claims and Formula Quality

According to the regulator, two popular infant formulas—NAN Excella Pro Stage 1 and Lactogen Pro 1—breached statutory advertising and marketing norms:

• In the case of NAN Excella Pro Stage 1, the regulator flagged specific marketing claims regarding "5 HMOs" (Human Milk Oligosaccharides) and "Whey Protein" published on digital platforms.
• For Lactogen Pro 1, the authority took issue with promotional claims asserting that its "Whey Protein" was "easy to digest".

The FSSAI noted that these marketing representations contravene Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020, which strictly prohibits promotional claims intended to artificially enhance the saleability of infant food. The practices also violate Section 3 of the Infant Milk Substitutes, Feeding Bottles and Infant Foods (Regulation of Production, Supply and Distribution) Act, 1992, which broadly bars the direct or indirect advertisement and promotion of infant substitutes.

In addition to marketing non-compliance, laboratory testing uncovered quality deficiencies in a third product. A sample of a follow-up infant formula manufactured by Nestle India was found to be sub-standard due to insufficient biotin content during laboratory analysis. A subsequent re-analysis conducted by a referral laboratory confirmed that the sample failed to conform to the statutory biotin levels mandated under the 2020 infant nutrition framework.

Stock Reaction and Market Impact

Reacting to the regulatory disclosure, Nestle India shares fell as much as 2.85% to an intraday low of ₹1,332.80 on the BSE.

The stock had touched a 52-week high of ₹1,553 in August 2026, while its 52-week low stood at ₹1,145.10 in October 2025. The stock had already lost roughly 8% over the past month, and the latest legal developments have added to the short-term pressure.

Strategic Implications for Investors

The Milk Products and Nutrition segment forms the bedrock of Nestle India's business, historically contributing over 30% of the company's total domestic revenue.

For Dalal Street, regulatory enforcement in the infant nutrition segment represents a critical risk factor:

• Brand Perception and Consumer Trust: Unlike discretionary snacks, infant nutrition relies heavily on medical endorsement, parent trust, and stringent adherence to safety standards. Scrutiny regarding nutrient non-conformance or banned promotional tactics risks dampening sales momentum.
• Broader Regulatory Clampdown: The FSSAI has intensified surveillance over misleading health claims, label declarations, and e-commerce product listings across the packaged foods sector, having issued numerous notices to leading consumer companies in recent months.
• Potential Financial Penalties: The filing of formal adjudication proceedings introduces legal costs and potential financial penalties under the Food Safety and Standards Act, while creating a regulatory overhang on Nestle India's market valuation until the matters reach a resolution.

Tags: Nestle India FSSAI BSE NSE FMCG Sector Infant Nutrition